Analysts Issue Forecasts for PTCT FY2025 Earnings

PTC Therapeutics, Inc. (NASDAQ:PTCT) – Cantor Fitzgerald issued their FY2025 EPS estimates for shares of PTC Therapeutics in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska forecasts that the biopharmaceutical company will post earnings per share of ($2.84) for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $76.00 target price on the stock. The consensus estimate for PTC Therapeutics’ current full-year earnings is ($4.75) per share.

PTC Therapeutics (NASDAQ:PTCT) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($1.39) EPS for the quarter, topping analysts’ consensus estimates of ($1.54) by $0.15. The company had revenue of $196.79 million during the quarter, compared to the consensus estimate of $173.51 million. During the same quarter in the previous year, the company posted ($1.76) earnings per share.

PTCT has been the topic of a number of other research reports. JPMorgan Chase & Co. increased their price target on PTC Therapeutics from $51.00 to $62.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 19th. Robert W. Baird increased their target price on shares of PTC Therapeutics from $52.00 to $70.00 and gave the stock an “outperform” rating in a report on Tuesday, December 3rd. Morgan Stanley upgraded shares of PTC Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $45.00 to $67.00 in a report on Friday, December 13th. Raymond James initiated coverage on shares of PTC Therapeutics in a report on Thursday, October 10th. They set a “market perform” rating on the stock. Finally, StockNews.com lowered PTC Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $55.00.

PTC Therapeutics Stock Performance

Shares of NASDAQ PTCT opened at $45.08 on Wednesday. The stock has a 50 day moving average price of $45.25 and a 200 day moving average price of $39.09. The firm has a market capitalization of $3.48 billion, a price-to-earnings ratio of -7.59 and a beta of 0.62. PTC Therapeutics has a 52-week low of $23.58 and a 52-week high of $54.16.

Institutional Trading of PTC Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Janney Montgomery Scott LLC boosted its stake in shares of PTC Therapeutics by 8.3% in the fourth quarter. Janney Montgomery Scott LLC now owns 5,965 shares of the biopharmaceutical company’s stock worth $269,000 after buying an additional 455 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in PTC Therapeutics by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,782 shares of the biopharmaceutical company’s stock valued at $104,000 after acquiring an additional 492 shares during the period. KBC Group NV raised its position in PTC Therapeutics by 29.2% during the third quarter. KBC Group NV now owns 2,232 shares of the biopharmaceutical company’s stock worth $83,000 after acquiring an additional 504 shares during the period. Creative Planning increased its stake in shares of PTC Therapeutics by 8.1% during the third quarter. Creative Planning now owns 10,944 shares of the biopharmaceutical company’s stock worth $406,000 after purchasing an additional 816 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in PTC Therapeutics by 6.1% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 15,413 shares of the biopharmaceutical company’s stock valued at $572,000 after buying an additional 884 shares in the last quarter.

Insider Transactions at PTC Therapeutics

In other PTC Therapeutics news, VP Mark Elliott Boulding sold 85,600 shares of PTC Therapeutics stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $52.26, for a total transaction of $4,473,456.00. Following the completion of the sale, the vice president now owns 92,389 shares of the company’s stock, valued at approximately $4,828,249.14. The trade was a 48.09 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Christine Marie Utter sold 17,800 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $51.77, for a total value of $921,506.00. Following the completion of the sale, the chief accounting officer now owns 52,428 shares in the company, valued at approximately $2,714,197.56. This represents a 25.35 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 211,737 shares of company stock worth $10,920,687. Insiders own 5.50% of the company’s stock.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.